Wire

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

News Plus

Welcome, one more step

The cross-newsroom layer: who covered a story, who didn’t, and how each one worded it. Plus your own news, on every device.

Follow your news

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email

See the coverage

  • Headlines side by side
  • Who reported first
  • Every newsroom clip, from every platform
  • Every newsroom photo on a story

Go deeper

  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Wire

Free stays free: the live wire, Not Everywhere, the brief, five follows and five Duki questions a day.

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

News Plus · Ask Duki

Keep asking Duki

A free account gets five questions a day. News Plus lifts the daily limit.

Also in News Plus

  • The whole archive
  • Headlines side by side
  • Who reported first
  • The Desk, every hour
BizportalEconomy

SpaceX Enters US Mobile Market, Teva Shares Surge on FDA Approval

Translated & summarized from Bizportal by baba

BusinessNeutral tone

Hebrew · Sole source

SpaceX is poised to enter the US mobile market after acquiring spectrum rights for an estimated $8 billion, causing major US carriers' stocks to fall. Simultaneously, Teva Pharmaceutical's shares rose 4% pre-market after the FDA approved its new monthly schizophrenia injection, WELTRUZA. Wall Street futures indicated a positive opening amid concerns over AI valuations, rising bond yields, and oil prices. OpenAI projected strong revenue growth, offering some support to tech stocks.

The story in 5 lines · by baba

  • SpaceX is set to enter the US mobile market after acquiring spectrum rights for approximately $8 billion.
  • Teva Pharmaceutical's stock surged 4% pre-market following FDA approval for its new schizophrenia injection, WELTRUZA.
  • Major US mobile carriers like T-Mobile, AT&T, and Verizon saw their shares drop between 5% and 8% due to SpaceX's move.
  • Wall Street futures pointed to a positive open, with Nasdaq 100 futures up 0.8%, amid mixed market signals.
  • OpenAI projected its annual revenue run rate to reach at least $70 billion by year-end, boosting tech sentiment.

Wall Street futures indicated a positive opening after a day of declines in tech stocks and sharp fluctuations in bond and oil markets. Pre-market trading showed the Nasdaq 100 futures up about 0.8%, S&P 500 futures up 0.3%, and Dow Jones futures up 0.1%. Falling oil prices and a recovery in AI stocks supported the indices, but a significant shift is occurring in the telecommunications sector. Elon Musk's SpaceX is nearing a full entry into the US mobile market, causing shares of the three major carriers to drop between 5% and 8% in early trading. SpaceX is reportedly acquiring a nationwide frequency spectrum package from investment firm Green Management for an estimated $8 billion, enabling it to expand its Starlink mobile service. This move has sent shares of T-Mobile, AT&T, and Verizon down significantly, with European telecom stocks also experiencing declines.

In Israeli news, Teva Pharmaceutical Industries is in focus after the FDA approved WELTRUZA, its monthly subcutaneous injection of olanzapine for adults with schizophrenia. This is the first such treatment that does not require medical supervision after each injection. Teva's stock rose about 4% in pre-market trading in New York, reaching approximately $41. The stock had already gained about 2% on the Tel Aviv Stock Exchange. Analysts estimate the drug's peak annual sales could range from $400 million to over $1 billion. This approval marks Teva's second long-acting schizophrenia injection, following UZEDY, and is seen as a significant commercial event in the $9 billion schizophrenia drug market.

Broader market concerns include the fear that AI investments are outpacing revenue generation, rising US Treasury yields to 24-year highs, and the potential for continued high energy prices due to the Middle East conflict. Despite these factors, some companies are showing significant business improvements. OpenAI has projected its annual revenue run rate to reach at least $70 billion by year-end, a substantial increase from $50 billion in September, boosting tech stocks. However, the market is also watching for the upcoming Q3 earnings season, with S&P 500 companies expected to show strong profit and revenue growth, though high interest rates pose a challenge for expanding multiples.

BizportalOther · Tel Aviv

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

News Plus · Follows

You’ve used your five follows

News Plus follows as many newsrooms, topics and people as you like, with alerts for each in the app.

Your follows5 of 5 on the free plan
Or swap one out in Following

Also in News Plus

  • Alerts for what you follow
  • Hide read stories
  • The daily brief by email
  • Your reading diet
EconomyTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

News Plus · Follows

You’ve used your five follows

News Plus follows as many newsrooms, topics and people as you like, with alerts for each in the app.

Your follows5 of 5 on the free plan
Or swap one out in Following

Also in News Plus

  • Alerts for what you follow
  • Hide read stories
  • The daily brief by email
  • Your reading diet

Mentioned

Related stories · 1

Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.

Open the Wire